Anti-malarial medication hydroxychloroquine and HIV The World Health Organization (WHO) has announced that the combination of the drug, lopinavir and ritonavir, is no longer offered to Covid patients. In a statement on Saturday, the International Steering Committee said the trial was part of a decision by the International Steering Committee not to reduce the death toll for Covid patients treated in the hospital.
The study also found that studies conducted in different countries on the use of these drugs as a preventive treatment for those who were not in the hospital were not affected.
Proper care; Remedezivir; Trials for coviduct therapy are currently being conducted in five categories: hydroxychloroquine, lopinavir, ritonavir, and lopinavir-ritonavir combination.
WHO Director General Tedros Athanom Gabrielos said the clinical trials are being conducted on 5500 patients from 39 countries and an interim report is expected to be released soon.
Content Highlights: Coronavirus WHO